Royalty Pharma: Inaprubahan ng FDA ang MYQORZO (aficamten) ng Cytokinetics para sa oHCM

Inaprubahan ng FDA ang NDA para sa MYQORZO (aficamten) sa symptomatic obstructive hypertrophic cardiomyopathy. Kumikita na ngayon ang Royalty Pharma ng 4.5% royalty sa mga benta hanggang $5 billion at 1% pagkatapos, kasama ang 1.9x repayment sa $275 million na drawn capital sa loob ng 10 taon. Maaaring kumuha pa ang Cytokinetics ng karagdagang $175 million sa loob ng 12 buwan, na mag-uudyok ng karagdagang 1.9x repayments.

Mahahalagang fact

Na-file: Dis 22, 2025, 04:37 PM
Kaganapan: Pag-apruba ng FDA
Direksyon: Positibo
Kumpanya: RPRXRoyalty Pharma
Asset: aficamten
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

8-K NY false 0001802768 0001802768 2025-12-19 2025-12-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 Royalty Pharma plc (Exact Name of Registrant as Specified in its Charter) England and Wales 001-39329 98-1535773 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Identification No.) 110 East 59 th Street New York , New York 10022 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (212) 883-0200 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if

SEC 8-K